Mankind Pharma slips 4% on Beige's likely 3% stake sale via block deal

According to media reports, Beige Ltd, an affiliate of private equity firm ChrysCapital, was looking to offload 2.90 per cent stake in the drugmaker through block deals

Mankind Pharma
Mankind Pharma | Photo: Website
SI Reporter Mumbai
2 min read Last Updated : Mar 26 2024 | 11:54 AM IST
Shares of Mankind Pharma slipped 4 per cent to Rs 2,117 on the National Stock Exchange (NSE) in Tuesday’s intra-day trade after over 3 per cent of its equity changed hands via block deals.

Till 11:13 am; as many as 14.2 million equity shares, representing 3.5 per cent of total equity of the pharma giant, changed hands on the NSE, exchange data showed.

The stock erased its intra-day losses and was trading 1 per cent lower at Rs 2,194.55 at 11:45 am. The names of the buyers and sellers of the deal were not known.

According to media reports, Beige Ltd, an affiliate of private equity firm ChrysCapital, was looking to offload 2.90 per cent stake in the drugmaker through block deals. The offer price for the transaction was expected to be around Rs 2,103-2,214 apiece.

As on December 31, 2023, Beige Ltd held 11.98 million equity shares or 2.99 per cent of total equity of Mankind Pharma, according to shareholding pattern data.

Mankind Pharma is principally engaged in the manufacturing of pharmaceuticals and health care products. The company made its stock market debut on May 9, 2023. The stock had hit a record high of Rs 2,297.40 on February 8, 2024. Today, it was trading at a 96 per cent premium over its issue price of Rs 1,080 per share.

During the December 2023 quarter (Q3FY24), Mankind Pharma’s revenue from operations increased 25 per cent year-on-year (YoY) to Rs 2,607 crore as compared to Rs 2,091 crore for Q3FY23.

The EBITDA has grown by 39 per cent on a YoY basis to Rs 611 crore with the margin expansion of 2.4 bps to 23.4 per cent.  Profit after tax jumped 55 per cent YoY at Rs 460 crore.

The margin improvement was driven by an increase in the gross margin of 0.7 per cent and the balance was supported by operating leverage being achieved due to strong revenue growth. The gross margin improved on account of favorable sales mix and the price increase effect, which was undertaken in the prior quarters, according to the management.

The company also has aggressive plans to expand its consumer healthcare business and increase the market share of key consumer healthcare brands, such as Manforce, Prega News and Gas-o-Fast.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Stock MarketBuzzing stocksMankind PharmaMarketsChrys Capitalblock deal norms

First Published: Mar 26 2024 | 11:54 AM IST

Next Story